Notably, the pretreatment CD4+CD25+FoxP3+Treg cell count of patients from the AD remission group linearly correlated to their pretreatment EASI significantly (r = 0.95, P < 0.0001, Figure 1(b)), whereas no such correlation was observed in patients from the AD active group (Figure 1(c)). This evidence concerns the gene FOXP3 and Alzheimer disease.